[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO995433L - Protease-inhibitorer - Google Patents

Protease-inhibitorer

Info

Publication number
NO995433L
NO995433L NO995433A NO995433A NO995433L NO 995433 L NO995433 L NO 995433L NO 995433 A NO995433 A NO 995433A NO 995433 A NO995433 A NO 995433A NO 995433 L NO995433 L NO 995433L
Authority
NO
Norway
Prior art keywords
alkyl
het
6alkyl
6alkenyl
cycloalkyl
Prior art date
Application number
NO995433A
Other languages
English (en)
Other versions
NO995433D0 (no
Inventor
Robert W Marquis
Yu Ru
Daniel Frank Veber
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO995433L publication Critical patent/NO995433L/no
Publication of NO995433D0 publication Critical patent/NO995433D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I): R4 R3 R1 N-f)n O hvor: d) YerArellerNR1R2; R1 er R", R"C(O), R"C(S), R"SO2, R"OC(O), R"R'NC(O) eller R"R'NC(S); R2 er H, Ci-ealkyl, C2-6alkenyl, Ar-Co-6alkyl eller Hel-CQ.Qa\ky\; R3 er H, C2-6alkenyl, C2-6alkynyl, Het, Ar eller Ci-ealkyl eventuelt substituert med OR1, SR1, NR'2, N(R')C(O)OR", CO2R', CO2NR'2, N(C=NH)NH2, Het eller Ar; _ R4 er H, Ci.ealkyl, C2-6alkenyl, Ar-Co-6alkyl eller Het-Cn-ealkyl; R5, R-V2' er - Ar-CO-6alkyl, Het-C0.6alkyl, adamantyl-C(O)- Ar-C(O)-. Het-C(O)- eller; R6 er R", R"C(0), R"C(S), R"SO2, R"OC(O), R"R'NC(O). R"R'NC(S),eller R"OC(O)NR'CH(R*)C(O); R7 er Ca.gcykloalkyl-Co-ealkyl, Ar-Crj-ealkyl, Het-Cø-ealkyl, Ar- Crj.ealkoksy, Het-Crj-ealkoksy eller C-|-6alkyl eventuelt substituert med OR1, SR', NR'2, N(R')C(O)OR", C02R1, CO2NR'2, N(C=NH)NH2, Het eller Ar; R* er H, Ci^alkyl. C2-6alkenyl, Cs^cykloalkyl-CQ-S-alkyl, Ar-Co_6alkyl, Het-Crj-6alkyl; hver R' er uavhengig H, C-i^alkyl, C2-ealkenyl, Ar-Co-6alkyl eller Het-Co-ealkyl; hver R" er uavhengig C-i^alkyl, C3_6cykloalkyl-Co-6-alkyl, Ar-Co-6alkyl eller Het-Crj-ealkyl; R1" er H, C^øalkyl, Ca-scykloalkyl-Co-ealkyl, Ar-Cø-ealkyl eller Het- Z er C(O) eller CH2; og ner 1, 2 eller 3; eller et farmasøytisk godtagbart salt derav, som er inhibitorer av cystein- proteaser, spesielt cathepsin K og er nyttige ved behandling av sykdommer hvor hemning av bentap er en faktor.
NO995433A 1997-05-08 1999-11-05 Protease-inhibitorer NO995433D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4686597P 1997-05-08 1997-05-08
PCT/US1998/009192 WO1998050534A1 (en) 1997-05-08 1998-05-06 Protease inhibitors

Publications (2)

Publication Number Publication Date
NO995433L true NO995433L (no) 1999-11-05
NO995433D0 NO995433D0 (no) 1999-11-05

Family

ID=21945814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995433A NO995433D0 (no) 1997-05-08 1999-11-05 Protease-inhibitorer

Country Status (18)

Country Link
US (1) US6369077B1 (no)
EP (1) EP0991753A4 (no)
JP (1) JP2001525809A (no)
KR (1) KR20010012316A (no)
CN (1) CN1255162A (no)
AU (1) AU7288598A (no)
BR (1) BR9808502A (no)
CA (1) CA2289010A1 (no)
CO (1) CO4950617A1 (no)
HU (1) HUP0001285A3 (no)
IL (1) IL131661A0 (no)
MA (1) MA26494A1 (no)
NO (1) NO995433D0 (no)
PE (1) PE73799A1 (no)
PL (1) PL336625A1 (no)
TR (1) TR199902752T2 (no)
WO (1) WO1998050534A1 (no)
ZA (1) ZA983843B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0004200A3 (en) * 1997-11-18 2001-04-28 Dupont Pharmaceuticals Res Lab Cyclic amine derivatives and their use as drugs
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
CO5180541A1 (es) * 1998-12-23 2002-07-30 Smithkline Beechman Corp Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
AU4796700A (en) * 1999-05-13 2000-12-05 Dupont Pharmaceuticals Research Laboratories, Inc. Ureido-substituted cyclic amine derivatives and their use as drug
AU5011300A (en) 1999-05-14 2000-12-05 Combichem, Inc. Cyclic amine derivatives and their uses
ES2250132T3 (es) 1999-05-18 2006-04-16 Teijin Limited Remedios preventivos para enfermedades asociadas a quimioquinas.
WO2001010439A1 (fr) * 1999-08-04 2001-02-15 Teijin Limited Antagonistes d'amine cyclique ccr3
CN1208318C (zh) * 1999-12-08 2005-06-29 帝人株式会社 环胺ccr5受体拮抗剂
ES2225297T3 (es) 1999-12-21 2005-03-16 Smithkline Beecham Corporation Antagonistas del receptor de urotensina ii.
AU780006B2 (en) 2000-03-06 2005-02-24 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
MXPA02009305A (es) * 2000-03-21 2003-03-12 Smithkline Beecham Corp Inhibidores de proteasa.
US6410566B1 (en) 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
AU2001275537A1 (en) 2000-06-20 2002-01-02 Wayne State University N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith
US8211916B2 (en) 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
US6395753B1 (en) * 2001-08-30 2002-05-28 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
DE60236206D1 (de) 2001-12-28 2010-06-10 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
JP2005515254A (ja) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション カテプシンｋ阻害剤として有用なシクロアルキルケトアミド誘導体
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
EP1562937A2 (en) 2002-06-24 2005-08-17 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
BRPI0406591B8 (pt) 2003-01-16 2021-05-25 Acadia Pharm Inc composto e composição farmacêutica
US20040192674A1 (en) * 2003-02-14 2004-09-30 Marquis Robert W. Cathepsin L inhibitors
US7384970B2 (en) 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
WO2005105075A1 (en) 2004-04-16 2005-11-10 Wayne State University Tri-substitued 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
US8017791B2 (en) 2003-03-28 2011-09-13 Wayne State University Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel, 3,6-disubstituted pyran derivatives
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
JP2008512461A (ja) * 2004-09-07 2008-04-24 スミスクライン・ビーチャム・コーポレイション 新規化合物
EP1794126B1 (en) 2004-09-27 2013-03-20 Acadia Pharmaceuticals Inc. Crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide hemi-tartrate
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
KR101351209B1 (ko) 2004-12-03 2014-02-06 머크 샤프 앤드 돔 코포레이션 Ｃｂ1 길항제로서 치환된 피페라진
CN101287727A (zh) * 2005-08-17 2008-10-15 先灵公司 新的高亲和力喹啉基激酶配体
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US8067415B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20100016289A1 (en) * 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
CA2637057A1 (en) * 2006-01-13 2007-07-26 Schering Corporation Diaryl piperidines as cb1 modulators
EP1973877A2 (en) * 2006-01-18 2008-10-01 Schering Corporation Cannibinoid receptor modulators
US20100179118A1 (en) * 2006-09-08 2010-07-15 Dainippon Sumitomo Pharma Co., Ltd. Cyclic aminoalkylcarboxamide derivative
US20090053329A1 (en) 2007-03-19 2009-02-26 Acadia Pharmaceuticals, Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
RU2010102478A (ru) * 2007-06-28 2011-08-10 Интэрвэт Интэрнэшнл Б.Ф. (NL) Замещенные пиперазины как антагонисты св1
WO2009005671A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
US8686152B2 (en) 2010-03-10 2014-04-01 Janssen Pharmaceutica Nv 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
ES2532763T3 (es) * 2010-03-10 2015-03-31 Janssen Pharmaceutica Nv Derivados de piperidina 4,4-disustituidos útiles como inhibidores de la dipeptidil peptidasa-1 (DPP-1)
MX2016013049A (es) 2014-04-04 2017-04-27 X-Rx Inc Inhibidores de autotaxina espirociclicos sustituidos.
WO2017015272A1 (en) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2804416A1 (de) * 1978-02-02 1979-08-09 Boehringer Mannheim Gmbh Neue purin-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
ES482439A0 (es) * 1978-07-18 1980-04-01 Hoechst Ag Procedimiento para la preparacion de nuevos derivados de 1-(4-aminopiperidino)-3,4-dihidroisoquinoleina.
US4301151A (en) * 1979-11-27 1981-11-17 Merck & Co., Inc. Long-lasting agonists of enkephalin
US4443461A (en) * 1981-09-10 1984-04-17 John Wyeth & Brother Limited N-[2-[[1-[1H-Indolylalkyl- or oxoalkyl]-4-piperidinyl]-amino]-2-oxoethyl]-arylcarboxamide derivatives
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
DK386089A (da) * 1988-08-12 1990-02-13 Japan Tobacco Inc Katekolderivater
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
EP0480044A4 (en) * 1990-03-30 1993-06-09 Japan Tobacco Inc. Novel 4h-3,1-benzoxazin-4-one derivative
US5514694A (en) 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
WO1994027967A1 (en) 1993-05-26 1994-12-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
DZ2285A1 (fr) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.

Also Published As

Publication number Publication date
EP0991753A1 (en) 2000-04-12
AU7288598A (en) 1998-11-27
WO1998050534A1 (en) 1998-11-12
JP2001525809A (ja) 2001-12-11
HUP0001285A3 (en) 2000-10-30
EP0991753A4 (en) 2001-07-11
CN1255162A (zh) 2000-05-31
ZA983843B (en) 1998-11-09
MA26494A1 (fr) 2004-12-20
TR199902752T2 (xx) 2000-06-21
HUP0001285A2 (hu) 2000-09-28
PE73799A1 (es) 1999-10-22
BR9808502A (pt) 2000-05-23
US6369077B1 (en) 2002-04-09
CO4950617A1 (es) 2000-09-01
PL336625A1 (en) 2000-07-03
NO995433D0 (no) 1999-11-05
CA2289010A1 (en) 1998-11-12
IL131661A0 (en) 2001-01-28
KR20010012316A (ko) 2001-02-15

Similar Documents

Publication Publication Date Title
NO995433L (no) Protease-inhibitorer
CA2262668A1 (en) Inhibitors of cathepsin k
PT87454A (pt) Heterocyclic ketones
WO1996016981A3 (en) Peptide compounds for prevention and/or treatment of no-mediated diseases
DE69720773T2 (de) SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
FI915819A0 (fi) Hiv- proteas-inhibitorer.
NO20013254D0 (no) Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
ID24846A (id) Turunan-turunan bifenilamidina
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
DE69810800D1 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
AR043271A1 (es) Compuestos de dihidropironas con heterociclos unidos y su uso en composicines farmaceuticas que poseen actividad inhibidora de hiv proteasa
DK0871626T3 (da) Triazoloner som apolipoprotein-B syntheseinhibitorer
NO20001200L (no) Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase
NO940019L (no) Fremgangsmåte for fremstilling av svovelholdige imidazolderivater
DE69813554D1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
ATE58135T1 (de) 1,3-oxathianderivate.
JPS6422898A (en) 2-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivative
ECSP982497A (es) Inhibidores de proteasas v
TH61368A (th) สารยับยั้งธรอมบินที่ประกอบด้วยกลุ่มอะมิโนไอโซควิโนลีน
HU217345B (hu) Helyettesített dihidro-piridin ftálamidsav származéka, és eljárás előállítására

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application